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Abstract
Background: Gay and bisexual men (GBM) are a major risk group for HIV acquisition, yet the majority of higher-risk
GBM test for HIV less often than recommended (3–6 monthly). HIV self-testing has the potential to increase testing
frequency and improve awareness of personal HIV status. HIV self-tests have been approved in some countries,
however there are concerns whether self-testing would increase HIV testing frequency enough to compensate for
the reduced sensitivity of self-tests in early infection. We describe here a randomised controlled trial to assess the
effectiveness of self-testing in increasing HIV testing frequency among higher-risk GBM, and its acceptability.
Methods/design: Participants are higher-risk HIV negative GBM (>5 partners or condomless anal intercourse in
previous 3 months; n = 350), including 50 GBM who tested for HIV over two years ago or never tested before
(‘infrequent-testers’). Participants are recruited from sexual health clinics and community-based organisations, and
randomised 1:1 to either self-testing or standard-care (routine clinic-based testing) arms. The trial employs a wait-list
control design: participants in the standard-care arm switch to self-testing arm in the second year, and gain access
to self-test kits. Participants in the self-testing arm receive four oral-fluid self-test kits at enrolment, with additional
kits provided on request. Demographics, sexual behaviour and HIV testing preferences are collected at baseline, and
the frequency and pattern of HIV and sexually transmissible infection (STI) testing is collected via online 3-monthly
questionnaires. The acceptability of self-testing is assessed at 12 months via an online questionnaire and in-depth
interviews. A 24-h telephone support is provided, with expedited follow-up of those with reactive self-test results.
The primary outcome is HIV testing frequency (mean number of HIV tests per person) over 12 months, and the
secondary outcomes are: mean number of STI tests (chlamydia, gonorrhoea, syphilis) per person; reasons for HIV
testing; and acceptability of HIV self-testing.
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Discussion: This is the first trial to evaluate the use of self-testing among GBM in Australia, and the first
internationally among infrequent testers. The study will provide evidence on whether self-testing increases HIV
testing frequency, and its acceptability among GBM. The findings will improve our understanding of self-testing
patterns, and whether GBM supplement or replace their existing testing routine.
Trial registration: Australian and New Zealand Clinical Trial Registration number: ACTRN12613001236785,
registered on November 12, 2013.
Keywords: HIV, MSM, Testing, Self-test, Home test
Background
Gay and bisexual men (GBM) are a major risk group for
HIV acquisition, and are disproportionately affected by
HIV in many countries [1]. The rates of HIV diagnoses
among GBM in high income countries including the
United States (US), United Kingdom (UK), and Australia
have increased over the past decade [2–5]. In Australia,
annual HIV diagnoses have increased by about 70 %
since 1999, and over two-thirds of new infections are di-
agnosed in GBM [5].
Regular testing is recognised as a key strategy for HIV
control. Reduction in risky sexual practices as a result of
the awareness of one’s HIV-positive status [6–8], and early
initiation of antiretroviral therapy, can substantially reduce
the risk of HIV transmission to sexual partners [9–11].
Mathematical modelling suggests that earlier diagnosis
and treatment of HIV-positive individuals could substan-
tially reduce population incidence [12]. A recent trial also
confirmed individual benefits with early initiation of anti-
retroviral therapy [13]. Clinical guidelines in many coun-
tries recommend that sexually active GBM should have at
least annual HIV testing, with 3–6 monthly testing for
higher-risk men [14].
HIV testing uptake among GBM in many middle and
high income countries is lower than the recommended
level [15–19], and less than a quarter of higher-risk
Australian GBM test every 3–6 months consistent with
the guidelines [20]. Between 8 and 34 % of HIV-positive
GBM in Australia [21, 22], New Zealand [23], US [24, 25],
UK [18], and Canada [26] are unaware of their HIV-
positive status. Mathematical modelling suggests that
individuals with undiagnosed HIV infections contribute
disproportionately to HIV transmission [27, 28]. A num-
ber of barriers to frequent HIV testing among GBM have
been identified, including: perceptions of being at low risk,
fear of an HIV-positive diagnosis, no symptoms or illness,
and structural barriers such as the need to return to
clinics for test results, facing difficulties with appoint-
ments, lack of time, and the cost and inconvenience asso-
ciated with attending clinics [17, 29, 30].
HIV self-testing has the potential to increase testing
uptake among GBM by overcoming some of the impedi-
ments to testing, particularly structural factors, improve
awareness of personal HIV-status, and give a greater sense
of control over men’s own health [31, 32]. HIV self-testing
kits have been approved for sale in the US [33] and UK
[34], and other countries including France and Kenya have
also changed regulations to allow self-testing for HIV [33].
Australian HIV testing policy was changed in July 2014 to
support self-testing for HIV, allowing manufactureres to
submit applications to the Therapeutics Goods Adminis-
tration for approval of self-tests [35], however no self-tests
have yet been approved for sale.
Surveys of GBM in Australia [36–40] and overseas indi-
cate that men are highly interested in accessing self-testing
if available [17, 41–46], and likely to increase their HIV test-
ing frequency [47]. However, concerns remain about errors
in interpreting test results by users, relatively lower sensitiv-
ity in early infections, emotional consequences of reactive
results and access to counselling, impact on STI testing fre-
quency, and linking people diagnosed with a self-test to
care [32, 48, 49]. HIV self-testing has been found to be
highly acceptable in a range of settings and populations
[50–52], with little or no evidence of harm associated with
self-testing (including anxiety, fear, worry, suicide, or harm
as a result of false results) [53]. A high proportion of GBM
in observational self-testing studies report that self-testing
is easy to perform, and express willingness to test again
using self-tests [54–58]. Almost all individuals (96 %) diag-
nosed with HIV in an unobserved field evaluation of oral
fluid self-testing in the US said they would access follow-up
confirmatory testing [59].
An oral fluid self-test (the OraQuick In-Home HIV
Test) was approved in the US on public health grounds
despite its relatively lower sensitivity in the field trials
[32], and acute HIV infections [60]. It was estimated that
in the first year of its availability, 2.8 million people in
the US would use the OraQuick In-Home HIV Test,
and even though there would be 3800 false-negative test
results (missed infections), this would be offset by
45,000 new infections being detected. Overall a reduc-
tion of more than 4000 new HIV transmissions in the
first year was estimated [32]. However, a subsequent
modelling study predicted that if used by GBM in Se-
attle, HIV prevalence would increase as men would re-
place conventional laboratory tests at clinics with a less
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sensitive self-test [61]. It is worth noting that the model
had important limitations, for example, not including
men who had not tested before and assuming men
would replace their routine testing with self-tests rather
than any supplementation [62]. A recent analysis based
on the Australian epidemic demonstrated that there
would be a public health benefit (detection of HIV infec-
tions that would have otherwise remained undiagnosed)
from self-testing if higher-risk GBM supplemented clinic-
based testing using the OraQuick self-test or previously
untested GBM used a self-test [63].
To date, there is evidence from only one, as yet unpub-
lished, randomised controlled trial (RCT) in Seattle that
access to HIV self-testing increases HIV testing frequency
among GBM [47]. However, to our knowledge, no studies
have specifically evaluated the use of HIV self-testing in
GBM who test relatively infrequently or have never tested
before. We describe here a randomised controlled trial
which aims to assess the effectiveness and acceptability of
HIV self-testing in higher-risk GBM who test more fre-
quently (last HIV test within the past two years) and less
frequently (last HIV test over two years ago or never
tested before).
Methods
Study design
This is a non-blinded wait-list control RCT with individuals
randomised in a 1:1 ratio to two study arms: intervention
(HIV self-testing) arm; and control (standard-care) arm.
Participants in each arm will be followed-up for two years.
Participants in the standard-care arm will switch to the
self-testing arm after one year of follow-up and get access
to self-testing in the second year (Fig. 1).
Participants
Participants include two testing subgroups: those who
had their last HIV test within the past two years (here-
after called ‘frequent testers’) and those who had their
last HIV test over two years ago, or have never tested
before (hereafter called ‘infrequent testers’).
Study objectives
The primary objective of this trial is to compare HIV test-
ing frequency between the self-testing and standard-care
arms. The secondary objectives are to compare the fre-
quency of sexually transmissible infection (STI) testing in-
cluding chlamydia, gonorrhoea and syphilis between the
two study arms; and to assess the reasons for HIV testing
and acceptability of HIV self-testing in the self-testing arm.
Study duration
The study will require 3 years to complete: 6 months
for recruitment, 24 months to complete the follow-up
and data collection, and 6 months for analysis and
reporting.
Ethical considerations
The study protocol has been approved by the South Eastern
Sydney Local Health District Human Research Ethics Com-
mittee (HREC) and the Alfred Hospital HREC. Additional
ethical approvals have been obtained from Victorian AIDS
Council Research Promotion and Ethics Committee, and
ACON Research Ethics Review Committee.
Inclusion and exclusion criteria
Participants are eligible if they: identify as gay or bisex-
ual men; are aged 18 years or above; are HIV negative
(either self-reported or based on clinical records); plan
to live in Australia for the next 2 years; and report any
condomless anal intercourse, or >5 male sexual partners
in the past 3 months. The eligibility criteria are adopted
from Australian clinical testing guidelines to recruit
higher-risk GBM [64], as they have the highest HIV inci-
dence in Australia [65]. Participants are excluded if they:
cannot speak and/or read English; cannot provide writ-
ten consent; or are unwilling or unable to comply with
all the requirements of the study.
Recruitment
Participants are recruited from large urban sexual health
centres and community-based organisations in Sydney,
Melbourne and Cairns, including: Sydney Sexual Health
Centre, Melbourne Sexual Health Centre, Cairns Sexual
Health Service, ACON Sydney (the largest gay men’s
health organisation in New South Wales), and the
Victorian AIDS Council, Melbourne. Promotion of the
study occurs through gay media, the study website [66]
and websites of participating organisations, social media
(Facebook), advertisements on Grindr (a mobile device
social networking application for GBM), and posters and
postcards at recruitment sites. Potentially eligible partici-
pants are informed about the study by recruitment staff
and clinicians. The clinical sites also use other strategies
for engaging potential participants, for example: eligible
participants receive a prompt when they complete a
computer-assisted self-interview for routine data collec-
tion; and study nurse receives an SMS (text message)
when an eligible patient completes a computer-assisted
self-interview. Participants are also able to express inter-
est in the study by completing an online form via the
study website. The study coordinator assesses the infor-
mation provided and refers eligible participants to the
recruitment sites.
All participants are required to attend one of the study
sites for recruitment. A dedicated study nurse at each
clinic or a designated staff member at the community
sites confirms participants’ eligibility via routinely col-
lected data on sexual behaviour or by using a paper-
based eligibility screening template. Those eligible are
given an information sheet, and the study procedures
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Fig. 1 Trial overview
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are explained to them. It is emphasised that the self-
test is not recommended for use within three months
of a potential exposure or risk event (the window
period), and that reactive self-test results must be con-
firmed by a conventional laboratory test at a clinic. Par-
ticipants are required to sign a written informed
consent at recruitment covering all trial procedures and
data collection.
Randomisation
Computer-generated randomisation codes, stratified by
testing group (frequent and infrequent testers), are pro-
duced by a biostatistician and sealed in opaque enve-
lopes by a research assistant not associated with the
trial. Once written consent is obtained, the recruitment
staff select the next randomisation envelope according
to the participant’s testing group and inform the partici-
pant of the study arm they are being assigned to – the
self-testing or standard-care arm.
Blinding
Given the nature of the intervention, it is not feasible to
blind the recruitment staff and participants to their
study arm allocation. However, recruitment staff are un-
aware of the allocation until the envelope is opened in
front of the participant. The statistician analysing RCT
data will be blinded to the study arms.
Study procedures
Intervention (self-testing) arm
Participants randomised to the self-testing arm have access
to oral fluid HIV self-test kits in addition to the usual
clinic-based HIV/STI testing and care. At enrolment,
participants in the self-testing arm receive four self-test kits
including the manufacturer-supplied step-by-step instruc-
tions and a web-link to an instructional video. Four self-test
kits provide a 12 month supply for higher-risk men who
test every 3–6 months consistent with the guidelines [64].
Participants are able to request additional kits, one at a
time, for a maximum of 12 kits in one year in case repeat
testing is needed or men test more frequently in relation to
risky sexual behaviour. Depending on participants’ prefer-
ence, additional self-test kits are either picked-up from the
study sites or sent by post in plain packaging. At the be-
ginning of the second year of follow-up, all participants
(including those switching from standard-care to the self-
testing arm) are eligible to collect four self-test kits from
study sites, or sent by post if requested. A central log of kits
dispatched is maintained to keep track of the number of
kits supplied to each participant. No training on performing
self-tests is provided at baseline to mimic a real-world sce-
nario where untrained individuals will purchase self-test
kits over-the-counter from pharmacies or online.
HIV self-testing kits The US Food and Drug Adminis-
tration approved ‘OraQuick In-Home HIV test’ (OraSure
Technologies Inc., Bethlehem, PA, USA) is being used
for HIV self-testing in this study (Fig. 2). It is a second
generation test which detects HIV 1/2 antibodies in oral
fluid specimens. The specimen is obtained by swabbing
the upper and lower gums using a collector device which
is then transferred to a solution, and the results are read
in 20–40 min [59]. The sensitivity and specificity of the
OraQuick self-test in the hands of untrained users is
91.7 % (95 % confidence interval [CI]: 84.2-96.3 %) and
99.9 % (95 % CI: 99.9-100.0 %), respectively [59]. Every
OraQuick kit is accompanied by step-by-step graphic
and written instructions and two booklets with general
information on HIV testing and interpretation of results.
The manufacturer-specified window period for Ora-
Quick self-test is three months [59], however published
data show that second generation antibody immunoas-
says detect HIV antibodies within 25–35 days after HIV
infection [67, 68]. The OraQuick self-test is a prelimin-
ary test and all reactive results must be confirmed with a
conventional laboratory test. As the test kit is packaged
for the US market, each self-test kit supplied to partici-
pants is prominently labelled with Australian telephone
numbers for support and emergencies.
Telephone support lines A 24-h telephone support line
staffed by the study coordinators on a rotation basis is
available to participants, providing support for the use of
self-test kits, interpretation of results, and advice for re-
active home test results. In addition, participants have
access to existing telephone support lines of participat-
ing sexual health centres. A log of calls to the telephone
support lines is maintained and the reason for each call
is recorded.
Follow-up of reactive self-tests Participants are advised
to inform the study coordinator of any reactive self-test
results. The responses to 3-monthly online question-
naires (see below) are also monitored for any reported
reactive self-test results. Any participant with a reactive
self-test result is advised by the study coordinator to
undergo confirmatory laboratory testing and offered ex-
pedited clinical review and supportive counselling at the
study clinics. If they prefer to go to a clinic other than
the study clinics, they are offered assistance in arranging
an appointment. The laboratory confirmation and man-
agement of participants with confirmed HIV diagnoses
will be based on the standard protocols at the respective
clinic, however their study involvement will cease.
Control (standard-care) arm
Participants randomised to the standard-care arm con-
tinue to access routine clinic-based HIV/STI testing and
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care at their preferred clinic, including clinics other than
the study clinics. In Australia, most laboratories use fourth
generation HIV screening immunoassays [69]. Supplemen-
tary HIV antibody, HIV p24 antigen, and Western Blot test-
ing are performed on specimens that are reactive by the
screening assay, and deemed positive if consistent with the
national case definition [70]. After 12 months, participants
in the standard-care arm switch to the self-testing arm and
follow the same procedures as the self-testing arm.
Outcome measures
The primary outcome is the mean number of HIV tests
per person over 12 months. The secondary outcomes
are: the mean number of STI (chlamydia, gonorrhoea,
syphilis) tests per person; reasons for HIV testing; and
the acceptability of HIV self-testing.
Data collection
Clinical data
HIV and STI testing data for the duration of the study
will be extracted from the patient management system
for all participants recruited at study clinics.
Surveys
Baseline All participants complete a self-administered on-
line survey on a handheld electronic device at enrolment.
The survey covers socio-demographics, sexual risk behav-
iour, HIV/STI testing history, attitudes to HIV self-testing,
opinions about treatments for HIV, and an HIV testing
self-efficacy scale measuring gay men's confidence in their
ability to undertake HIV testing [71].
3-monthly Participants in both arms of the study
complete a brief online survey every three months asking
the number, location, reasons for, and results of HIV self-
tests and HIV/STI tests at clinics and community sites,
and sexual risk behaviour since their last survey. Partici-
pants are also asked about the number of self-test kits they
used to test their sexual partner(s) or gave to someone
else to test at another time. If participants report episodes
of HIV/STI testing at clinics other than study clinics,
those clinics are contacted to obtain test results. Consent
for release of results is obtained at enrolment and mailed/
faxed to relevant clinics when obtaining results.
12 months At 12 months, a survey is conducted includ-
ing the same questions as the 3-monthly survey with
some additional questions about self-testing acceptabil-
ity, ease of use overall and for various steps of HIV self-
testing, participants’ experience using self-tests to test
themselves and their partner(s), if relevant, and their
preferences for accessing and using HIV self-testing in
the future.
Survey reminders
If participants have not completed a survey, they are
sent up to three reminders via email or SMS, each one
Fig. 2 OraQuick In-Home HIV Test kit contents: instruction booklet (flipchart design), specimen collection device, developer solution vial, pre-test
and post-test information booklets, pencil, and disposal bag (Source: http://www.oraquick.com)
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week apart. If surveys are not completed after three re-
minders, participants are sent a final SMS asking the
total number of HIV tests and the number of HIV self-
tests since their last survey.
In-depth interviews
About 25 participants in the self-testing arm will be
invited to participate in a face-to-face semi-structured in-
depth interview at the completion of 12 months follow-
up. Participants are asked at enrolment if they are willing
to be contacted for in-depth interviews. The interviews
will focus on collecting detailed information about their
HIV testing pattern prior to the study, their experience
using self-tests to test themselves and their partner(s) dur-
ing the study, any changes in their testing patterns and
sexual behaviour after getting access to self-testing, and
their opinions about HIV self-testing in the future. Partici-
pants from each of the following groups will be inter-
viewed: those who tested themselves using self-tests only;
those who tested at clinics and supplemented their testing
with self-tests; those who tested their partner(s) using self-
tests; and those who had a confirmed positive or false-
reactive self-test result.
Statistical analysis plan
All analyses will be conducted using Stata 14. The mean
HIV and STI testing frequency in each arm (self-testing
and standard-care) by testing subgroup (frequent and infre-
quent testers) will be assessed using an intention-to-treat
analysis at 12 months. The per-protocol analyses will in-
clude calculating: (i) the reasons for HIV testing; and (ii)
the acceptability of HIV self-testing in the self-testing arm.
The mean HIV testing frequency per person in the first
12 months will be calculated, excluding any tests per-
formed at enrolment. Only self-reported HIV tests where
there is a record of an HIV test occurring at a clinic or
community site will be included. The following tests will
be excluded from the testing frequency calculation: HIV
self-tests where participants did not obtain a result for any
reason; self-test kits used to test a partner(s) or given to
someone else; and confirmatory HIV tests following a re-
active self-test. STI testing will include episodes of testing
for chlamydia, gonorrhoea, or syphilis tests, and will be in-
cluded where there is a record of a test occurring at a
clinic or community site.
The effects of the intervention will be measured by
comparing the mean HIV testing frequency, the mean
STI testing frequency, and mean clinic-based HIV tests
in each arm by testing subgroup using a t-test. The rea-
sons for self-tests and clinic tests in the self-testing arm
will be compared using repeated measures logistic re-
gression clustered on individual. The acceptability ana-
lysis will be descriptive only. Differences in proportions
will be investigated using Chi2 statistics.
Sample size
In the analysis, we intend to assess the primary outcome
for the frequent and infrequent testers subgroups and
overall. For frequent testers, a sample size of 112 in each
arm will detect an increase in HIV testing frequency
from 1.5 tests per year to 2 tests per year (standard devi-
ation [SD]: 2.4) with 80 % statistical power and type I
error probability of 0.05. The frequency of 1.5 tests per
year is based on the results of a previous clinic based
RCT in Melbourne [72], and data from Australian sexual
health clinics [73]. For infrequent testers, a sample size
of 14 in each arm will detect an increase in HIV testing
frequency from 0.2 tests per year (assuming one HIV
test in the past five years based on clinic data [73]) to 1
test per year (SD: 0.7) with 80 % statistical power and
type I error probability of 0.05. On this basis, we conser-
vatively estimate a sample size of 300 frequent testers
and 50 infrequent testers for an overall sample size of
350. The sample size of 350 will achieve at least 80 %
statistical power to detect an overall increase from 1.5 to
2 tests per year (SD: 2.4) for the two groups combined.
Trial registration
The trial is registered with the Australian and New Zealand
Clinical Trial Registry [trial ID: ACTRN12613001236785,
registered on November 12, 2013].
Discussion
Gay and bisexual men are at an increased risk of acquiring
HIV infection, and the rates of HIV diagnoses in GBM
have increased in recent years. Yet, the uptake of HIV
testing among GBM in Australia and other countries is
lower than the recommended level, and a significant pro-
portion of HIV infections remain undiagnosed. HIV self-
testing has the potential to improve testing uptake and
frequency among GBM. To our knowledge, the FORTH
trial is the first in Australia to assess whether access to
HIV self-testing increases HIV testing frequency among
GBM, and the first internationally among GBM who test
less frequently or have never tested before.
A major strength of the FORTH trial is the focus on in-
frequent testers. A recent Australian study showed that in
addition to GBM using self-tests to supplement their
existing testing, there will be a public health benefit if pre-
viously untested GBM test for the first time using HIV
self-tests [63]. In Australia, about 20 % of GBM in
community-based samples reported their last HIV test
was over two years ago or have never tested for HIV [19].
In 2011, about 17 % of GBM in six US cities reported they
had never tested before for HIV [17]. An RCT in Seattle
showed that access to HIV self-testing significantly in-
creased HIV testing frequency among GBM over a
15 months period (3.6 vs. 5.3 tests per person) [47], how-
ever the study did not specifically explore the outcomes in
Jamil et al. BMC Infectious Diseases  (2015) 15:561 Page 7 of 10
infrequent testers. In addition, there are other methodo-
logical differences: our sample size is larger (350 vs. 230);
follow-up duration is longer (24 months vs. 15 months)
allowing us to assess the sustainability of the intervention;
and the wait-list design will allow us to assess the impact
of delayed access to self-testing on HIV testing frequency.
An important consideration when GBM start using self-
tests is whether they supplement or replace their routine
testing with self-tests [37]. Though cross-sectional surveys
of Australian GBM indicate that they are likely to test
more often if self-testing is available [36], our study will
provide conclusive evidence as to whether access to HIV
self-testing among GBM: increases testing frequency, and
to a level where a public health benefit can be achieved
[63]; leads men to supplement or replace their existing
testing; and leads untested men to test for HIV for the first
time. Also, the findings will improve our understanding of
the reasons for self-testing among GBM, and whether
men use self-tests to test themselves after risk events. We
are also asking participants about their preferences for fu-
ture self-testing delivery methods including online, phar-
macy, and clinics, to understand how men would prefer to
access self-testing when available.
A major concern in relation to HIV self-testing is that
it may lead to GBM testing less frequently for other STIs
including chlamydia, gonorrhoea and syphilis, for which
they would still need to attend clinics. The prevalence of
STIs is high in GBM, and repeat rectal chlamydia and
gonorrhoea infections have been associated with an in-
creased risk of HIV seroconversion [74]. Our study will
be able to assess whether access to HIV self-testing will
lead to a lower STI testing frequency in GBM.
Previous studies have indicated that GBM are willing
to use self-tests to test partners before sexual inter-
course, and there is potential for detecting undiagnosed
infections [75]. Although not a main outcome of this
study, we are collecting information about the number
of self-test kits participants used to test their partners
and the type of partners they tested. This will be further
explored in in-depth interviews to contextualise the use
of self-tests with partners, for example, whether men use
self-tests to negotiate safe sex, make decisions to have
sex without condoms and so on.
The study will contribute to the scarce literature inter-
nationally on the impact of self-testing on HIV testing
frequency among GBM. The study will provide evidence
on the level of testing that could be achieved with HIV
self-testing among Australian GBM, and whether men
supplement or replace their existing testing with self-
testing. The findings will improve our understanding of
the safety, effectiveness and acceptability of self-testing,
particularly among infrequent testers. The findings will
have important implications for self-testing policy, both
in Australia and internationally.
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